// App-Quantinova.ai

714 : Omalizumab responders analysis in nasal polyposis: A supplementary analysis of the co‐primary endpoints of POLYP 1 and POLYP 2 trials

Researchers

Presenter

  • Corren J

Principal Investigators

  • Wellings PH

  • Gevaert P

  • Bachert C

  • Mullol J

  • Jaumont X

  • Zhao R

  • Saenz R

  • Islam L

  • Omachi T

Medical Centers

  • Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States,

  • Clinical division of Otorhinolaryngology, Head & Neck Surgery, University Hospitals, Leuven, Belgium

  • Laboratory of Clinical Immunology, KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium

  • Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium,

  • Division of ENT Diseases, CLINTEC, Karolinska Institute, University of Stockholm, Stockholm, Sweden

  • Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain

  • Novartis AG, Basel, Switzerland

  • Genentech Inc., San Francisco, United States

  • Roche, Welwyn Garden City, United Kingdom

Locations

  • United States

  • Belgium

  • Sweden

  • Spain

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Omalizumab

  • Immunol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved